Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on treating rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative ...

Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), today announced that the European Commission (EC) has approved Emcitate® (tiratricol) ...

By leveraging AI platforms like Deep Docking™ and Enki™, Rakovina Therapeutics is poised to contribute to this new era of rapid medical advancements ... By using AI, we can review and optimize drug ...

Affinia Therapeutics, a gene therapy company with a pipeline of adeno-associated virus (AAV) gene therapies for devastating ...

CytoMed has generated the critical cell banks for the iPSC-derived hybrid of gamma delta T and Natural Killer cell technology and is currently undergoing process development into a potentially very ...

Acrivon Therapeutics said the Food and Drug Administration has granted Breakthrough Device designation for its ACR-368 OncoSignature assay, an immunofluorescence assay for the identification of ...

Unicycive Therapeutics, Inc. has announced the publication of a review in the Journal of Nephrological ... key findings from patient surveys and medical literature, identifying critical barriers ...

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company") today released a letter to shareholders from the Chairman of the Company's Board ...

In the preceding three months, 8 analysts have released ratings for Halozyme Therapeutics HALO ... products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing ...

RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...

In a recent transaction, Norry Elliot, the Chief Medical (TASE:PMCN) Officer of Adaptimmune Therapeutics PLC (NASDAQ ... to expedite the development and review of potentially significant ...